Arthneeti
TM

Themis Medicare Ltd

Q3 FY24Pharmaceuticals & Biotechnology

Themis Medicare Ltd Q3 FY24 Results & Presentation Highlights: Revenue, Margins & Order Book

Q3 FY24 investor presentation: what the company reported on revenue, margins and projects.

Price₹118
Market cap₹1.1K Cr
Updated24 Sept 2026
Read4 min read

Based on Themis Medicare Ltd's Q3 FY24 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.

The short version

Q3 FY24 Net Revenue: Rs. Q3 FY24 Financials: - EBITDA: Rs.

From Themis Medicare Ltd's Q3 FY24 earnings-call transcript · updated 24 Sept 2026.

Revenue & Sales Performance

  • Q3 FY24 Net Revenue: Rs. 82.51 Cr, down 7.06% year-on-year from Rs. 88.78 Cr in Q3 FY23 (Page 8).
  • Hospital Business grew by 19% year-on-year for 9M FY24 (Page 8, Page 6).
  • 9M FY24 Net Revenue: Rs. 283.94 Cr, up 3.55% year-on-year from Rs. 274.22 Cr in 9M FY23 (Page 9).
  • Management outlook: Focus on growing Hospital Business, export growth (over 40% in 9M FY24), and improved cash flows by controlling receivables (Page 6).

2 more points management made on revenue & sales performance

Profitability & Margins

See what Themis Medicare Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

The presentation does not explicitly mention any specific capex amounts, capacity expansion projects, or new plant developments with detailed status or timelines. However, the following relevant points can be noted: - Themis Medicare Ltd. has **state-of-the-art manufacturing facilities** in India: 1 Formulations plant and 2 APIs plants (Synthetic and Biotech) across Haridwar, Hyderabad, and Vapi. - Capacity details given for manufacturing include: - Tablets - 520 million per annum - Ointments - 9 million tubes per annum - Ampoules - 36 million per annum - Vials - 12 million per annum - Pre-filled syringes - 6 million per annum - Synthetic API capacities of 120 MT and 191 MT at respective locations.

2 more points management made on capital expenditure plans

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

5x potential
1KRM Ayurveda Ltd
Rev 1Mar 1
2Accretion Pharmaceuticals Ltd
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Themis Medicare Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The investor presentation does not explicitly report or provide details about order book, order inflow, or pending orders. The document primarily covers: - Financial performance (revenue, EBITDA, PAT) - Business segments and growth opportunities (Hospital Business, APIs) - Strategic focus and market expansion plans

2 more points management made on order book & pipeline

Themis Medicare Ltd — Quarterly revenue & net profit

Revenue Net profit Net loss
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹77 Cr, net profit ₹9 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Themis Medicare Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • Wockhardt Ltd (Q3 FY24)

    Net Sales Revenues for 9M FY24: INR 2,129 Cr. Key investor presentation takeaways from Wockhardt Ltd's Q3 FY24 investor presentation — and how it ranks against

  • NGL Fine Chem Ltd (Q3 FY24)

    Q3FY24 Revenue from Operations: ₹87.95 crore, up 22.27% year-on-year (YoY) from Q3FY23 ₹71.93 crore (Page 8). Key investor presentation takeaways from NGL Fine

  • Anuh Pharma Ltd (Q3 FY24)

    172.10 Cr, a 15% increase quarter-on-quarter and 31% year-on-year over 9M FY23. Key investor presentation takeaways from Anuh Pharma Ltd's Q3 FY24 investor pres

  • Bharat Parenterals Ltd (Q3 FY24)

    Revenue from operations: ₹58.8 crore (down 0.4% YoY) . Key investor presentation takeaways from Bharat Parenterals Ltd's Q3 FY24 investor presentation — and how

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Themis Medicare Ltd Q3 FY24 results?

Q3 FY24 Net Revenue: Rs. Q3 FY24 Financials: - EBITDA: Rs.

What is Themis Medicare Ltd share price analysis?

Themis Medicare Ltd currently shows a neutral. The stock trades at a P/E of N/A with a market cap of ₹1,142 Cr. Investors should review the full earnings analysis for detailed insights.

Is Themis Medicare Ltd planning capital expenditure?

The presentation does not explicitly mention any specific capex amounts, capacity expansion projects, or new plant developments with detailed status or timelines.

Keep Themis Medicare Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.